Nivalis Therapeutics Inc. (NVLS) shares fall following downgrade at Stifel Nicolaus

Nivalis Therapeutics Inc. (NASDAQ: NVLS) shares fell on Tuesday Nov 29 with heavier trade volume than normal after a number of analysts weighed in on the investing value of the stock with a downgraded rating.

U.S. stocks on Tuesday morning traded near break-even levels, with the main benchmarks switching in and out of negative territory

The Dow Jones Industrial Average DJIA, -0.09% was flat at 19,102. Meanwhile, the Nasdaq Composite COMP, +0.00% traded 18 points, or 0.1%, at 5,362.

The S&P 500 index SPX, -0.04% was off by 0.1%, or 2 points, at 2,199, with five of the 11 main sectors trading lower.

Analysts at Stifel Nicolaus downgraded shares of Nivalis Therapeutics Inc. (NASDAQ: NVLS) from Buy to Hold in a research note to investors today. With a rating of Hold on the stock, Nivalis Therapeutics Inc. has a 52-week high of $9.46. The one-year price target of $23.75 is above the opening price of $2.87, resulting a fair amount of other analysts to issue statements on the stock in recent days. Downgrades are more common when analysts believe that the future prospects for the security have dropped from the original recommendation, often caused by a considerable and crucial digression in the company’s actions, future direction or industry.

Shares of Nivalis Therapeutics Inc. (NASDAQ: NVLS) opened at $2.87 on Tuesday and has traded in a range between, $2.78 and $3.04, and last traded at $2.82, which represents a drop of $3.44 per share or -54.96% from the previous closing price.

Nivalis Therapeutics Inc. (NASDAQ: NVLS) currently has a market cap of 43.75M.

Nivalis Therapeutics Inc. (NASDAQ: NVLS) Average Daily Trading Volume

1,526,191 shares crossed the trading desk yesterday, higher than the norm, out of a total float 6,928,000. Significant increases in trading volume and price appreciation together could mean heavy volume accumulation by institutional investors.

While increased trading for short periods will not mean much, conversely, a trend of heavy trading volume on the buy side over a series of days or weeks sends a positive signal to market traders that institutions may be moving in, so institutional sponsorship is crucial.

Institutional sponsorship just refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors have substantial teams of analysts that investigate thousands of stocks. So watching their interests is a good way to make sure you are buying the right stocks.

Nivalis Therapeutics Inc. (NASDAQ: NVLS) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors and how they affect moving averages, traders are able to make make smarter trades.

With that in mind, Nivalis Therapeutics Inc. (NASDAQ: NVLS) now has a 50-day MA of $6.46 and 200-day MA of $5.84. It has traded in a 52-week range between $2.78 – 9.455 and today’s last price is 70.23%% lower than the 52 week high of $9.46.

Indeed, earnings growth is among the most important things to look at in regards to stock investing and, accordingly, investors seek companies that have grown their earnings at least 25% or more over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *